[HTML][HTML] Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
Background Despite unprecedented benefit from immune checkpoint inhibitors (ICIs) in
patients with mismatch repair deficient (dMMR)/microsatellite instability high (MSI-H) …
patients with mismatch repair deficient (dMMR)/microsatellite instability high (MSI-H) …
[HTML][HTML] Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer
G Mazzoli, R Cohen, S Lonardi, F Corti, E Elez… - European Journal of …, 2022 - Elsevier
Background Immune checkpoint inhibitors yielded unprecedented outcomes in patients with
mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal …
mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal …
Circulating tumor DNA as a marker of minimal residual disease after radical resection of colorectal liver metastases
F Marmorino, M Prisciandaro, M Giordano… - JCO precision …, 2022 - ascopubs.org
PURPOSE Prognostic tools to estimate the risk of relapse for patients with liver-limited
metastatic colorectal cancer (LL-mCRC) undergoing resection with curative intent are …
metastatic colorectal cancer (LL-mCRC) undergoing resection with curative intent are …
[HTML][HTML] Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with …
P Manca, F Corti, R Intini, G Mazzoli, R Miceli… - European Journal of …, 2023 - Elsevier
Abstract Background Immune checkpoint inhibitors (ICIs) are the standard treatment in
patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) …
patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) …
[HTML][HTML] Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer
V Nasca, F Barretta, F Corti, S Lonardi… - … for immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background Immune checkpoint inhibitors (ICIs) show a tremendous activity in microsatellite
instability-high (MSI-H) metastatic colorectal cancer (mCRC), but a consistent fraction of …
instability-high (MSI-H) metastatic colorectal cancer (mCRC), but a consistent fraction of …
Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin
F Ghelardi, A Raimondi, F Morano, G Randon… - Clinical Colorectal …, 2023 - Elsevier
Introduction Pseudomyxoma peritonei (PMP) is a rare, slow growing tumor, traditionally
considered chemoresistant. The only curative approach is cytoreductive surgery (CRS) …
considered chemoresistant. The only curative approach is cytoreductive surgery (CRS) …